John W. Hubbard Ph.D., FCP

John brings more than 35 years of leadership experience in the biopharmaceutical and CRO industries to help guide Flourish Research on its mission and strategy to enhance pharmaceutical development across their clinical trial site network and improve human health.

John was President and CEO of Bioclinica, a leading provider of medical imaging, clinical technology and global clinical site network development services. Under his leadership, the company doubled in size, completed four acquisitions and expanded its customer base to more than 400 companies, including the top 100 bio-pharmaceutical companies and top ten CROs.

Prior to Bioclinica, he was Senior Vice President and Worldwide Head of Development Operations at Pfizer. He was responsible for global drug development of more than 500 clinical trials per year. He was a member of the Portfolio Strategy and Investment Committee, Co-Chairman of the Clinical and Medical Excellence Innovation Board, Co-Chairman of the early Development Committee, Chair of the Enterprise Precision Medicine Steering Committee, and member of the Worldwide Research & Development (R&D) Executive Leadership Team. John also served on the executive taskforce that redesigned Pfizer’s global R&D organization in 2011. Before joining Pfizer, he was Group President of ICON plc’s Global Clinical Research Division and also held executive positions at ICSL-Clinical Studies, Parexel International Corporation and Hoechst Marion Roussel (now Sanofi).

John was a founding member of the Board of Directors of TransCelerate Biopharma, Inc., is an Executive Committee Member Emeritus on the Clinical Trials Transformation Initiative (CTTI). He is a former board member of Agile Therapeutics, Science 37, Life Sciences Pennsylvania, and was former Chairman of the Board of the Association of Clinical Research Organizations (ACRO). As part of his role as a Healthcare Strategic Advisory Board Member to Genstar Capital, John advises the firm on healthcare investments and serves as a board member on their portfolio companies (Flourish Research and Chairman of Signant Health). He is also on the Board of Advarra and Chairman of the Board of the Precision Medicine Group.

John has authored or co-authored 85 published abstracts and peer-reviewed articles in cardiovascular pharmacology, clinical pharmacology, and drug development. He has received numerous industry awards and was recognized by Pharma Voice as one of the 100 Most Inspirational People of 2016.

John received a Bachelor of Science in Experimental Psychology from the University of Santa Clara and a Doctorate in Cardiovascular Psychophysiology from the University of Tennessee. He was a National Institute of Health Postdoctoral Fellow in Cardiovascular and Clinical Pharmacology at the University of Texas Health Sciences Center. He is a Board-Certified Diplomate in Applied Pharmacology and a Fellow of the American College of Clinical Pharmacology.